Brind.
  1. I-Mab presented clinical data for Givastomig, combining it with nivolumab and mFOLFOX6, while Trump-era tariffs benefited AI stocks.

AI stocks are benefiting from Trump tariffs and onshoring, alongside potential merger talks involving Northern Trust and Bank of New York Mellon.

5 reports, 0 independent Updated Jul 8
Gone quiet
Reports
5
Developments
4
Repetition
40%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

AI stocks are benefiting from Trump tariffs and onshoring, alongside potential merger talks involving Northern Trust and Bank of New York Mellon.

Who's involved

What this event is mainly about
Donald TrumpNorthern Trust

How it developed

Newest first. Tap a step to see who reported it.
  1. Merger talks between The Bank of New York Mellon and Northern Trust were prompted by the firms to assert independence, while both offer asset servicing and money management services.Sub-event
  2. New potential merger talks between AI stocks and BNY Mellon are underway, benefiting from Trump tariffs.
  3. Bank of New York Mellon expressed interest in merging with Northern Trust.
  4. The potential merger faces antitrust hurdles, despite a light regulatory approach from the Trump administration.

Keep exploring

Part of

I-Mab presented clinical data for Givastomig, combining it with nivolumab and mFOLFOX6, while Trump-era tariffs benefited AI stocks. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet
  • Unknown outlet